Search research articles
Contact Us
Filters
Showing results (1-10 of 20) with videos related to
Page
of 2
Sort By:
Cancer Chemotherapy and Pharmacology
|
April 3, 2010
Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis
Mohamed Bouchahda, Abdoulaye Karaboué, Raphaël Saffroy, et al.
JCO Precision Oncology
|
October 5, 2020
Undetectable <i>RAS</i>-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With <i>RAS</i>-Mutant Metastatic Colorectal Cancer
Mohamed Bouchahda, Raphael Saffroy, Abdoulaye Karaboué, et al.
Clinical Pharmacokinetics
|
July 10, 2016
Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study
Francis Lévi, Abdoulaye Karaboué, Marie-Christine Etienne-Grimaldi, et al.
Cancer Chemotherapy and Pharmacology
|
April 20, 2010
Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability
Francis Lévi, Abdoulaye Karaboué, Lee Gorden, et al.
JCO Clinical Cancer Informatics
|
January 18, 2019
Home-Based e-Health Platform for Multidimensional Telemonitoring of Symptoms, Body Weight, Sleep, and Circadian Activity: Relevance for Chronomodulated Administration of Irinotecan, Fluorouracil-Leucovorin, and Oxaliplatin at Home-Results From a Pilot Study
Pasquale Innominato, Sandra Komarzynski, Abdoulaye Karaboué, et al.
Cancer
|
July 29, 2009
Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer
Mohamed Bouchahda, René Adam, Sylvie Giacchetti, et al.
Cancers
|
February 25, 2022
Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer
Abdoulaye Karaboué, Thierry Collon, Ida Pavese, et al.
The Oncologist
|
November 18, 2006
Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer
Dany Gholam, Sylvie Giacchetti, Catherine Brézault-Bonnet, et al.
Cancer Medicine
|
April 23, 2020
Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial
Pasquale F Innominato, Annabelle Ballesta, Qi Huang, et al.
International Journal of Cancer
|
December 3, 2020
Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5-fluorouracil and leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: Results from the International EORTC 05011 Trial
Pasquale F Innominato, Abdoulaye Karaboué, Christian Focan, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 20) with videos related to
Sort By:
Page
of 2
Cancer Chemotherapy and Pharmacology
|
April 3, 2010
Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis
Mohamed Bouchahda, Abdoulaye Karaboué, Raphaël Saffroy, et al.
JCO Precision Oncology
|
October 5, 2020
Undetectable <i>RAS</i>-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With <i>RAS</i>-Mutant Metastatic Colorectal Cancer
Mohamed Bouchahda, Raphael Saffroy, Abdoulaye Karaboué, et al.
Clinical Pharmacokinetics
|
July 10, 2016
Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study
Francis Lévi, Abdoulaye Karaboué, Marie-Christine Etienne-Grimaldi, et al.
Cancer Chemotherapy and Pharmacology
|
April 20, 2010
Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability
Francis Lévi, Abdoulaye Karaboué, Lee Gorden, et al.
JCO Clinical Cancer Informatics
|
January 18, 2019
Home-Based e-Health Platform for Multidimensional Telemonitoring of Symptoms, Body Weight, Sleep, and Circadian Activity: Relevance for Chronomodulated Administration of Irinotecan, Fluorouracil-Leucovorin, and Oxaliplatin at Home-Results From a Pilot Study
Pasquale Innominato, Sandra Komarzynski, Abdoulaye Karaboué, et al.
Cancer
|
July 29, 2009
Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer
Mohamed Bouchahda, René Adam, Sylvie Giacchetti, et al.
Cancers
|
February 25, 2022
Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer
Abdoulaye Karaboué, Thierry Collon, Ida Pavese, et al.
The Oncologist
|
November 18, 2006
Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer
Dany Gholam, Sylvie Giacchetti, Catherine Brézault-Bonnet, et al.
Cancer Medicine
|
April 23, 2020
Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial
Pasquale F Innominato, Annabelle Ballesta, Qi Huang, et al.
International Journal of Cancer
|
December 3, 2020
Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5-fluorouracil and leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: Results from the International EORTC 05011 Trial
Pasquale F Innominato, Abdoulaye Karaboué, Christian Focan, et al.
Page
of 2